# A Multicentre, Randomised, Double-blind, Placebo-parallel Controlled Phase Ⅲ Clinical Trial Evaluating the Efficacy and Safety of BXOS110 Injection in the Treatment of Acute Ischaemic Stroke Within 3 Hours of Onset.

> **NCT07520565** · PHASE3 · RECRUITING · sponsor: **Biocells (Beijing) Biotech Co.,Ltd** · enrollment: 1112 (estimated)

## Conditions studied

- AIS

## Interventions

- **DRUG:** BXOS110
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT07520565
- **Lead sponsor:** Biocells (Beijing) Biotech Co.,Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-19
- **Primary completion:** 2027-07
- **Final completion:** 2027-12
- **Target enrollment:** 1112 (ESTIMATED)
- **Last updated:** 2026-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07520565

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07520565, "A Multicentre, Randomised, Double-blind, Placebo-parallel Controlled Phase Ⅲ Clinical Trial Evaluating the Efficacy and Safety of BXOS110 Injection in the Treatment of Acute Ischaemic Stroke Within 3 Hours of Onset.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07520565. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*